Ordering Recommendation

Predicts risk of dose-related toxicity to 5-FU therapy. May be useful in dosage planning for individuals who will receive high-dose irinotecan, have personal or family history of sensitivity to irinotecan, or have experienced neutropenia while receiving irinotecan. 

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Two tubes of lavender (EDTA), pink (K2EDTA).

Specimen Preparation

Transport 3 mL whole blood in each tube. (Min: 1 mL in each tube)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Heparinized specimens. Frozen specimens in glass collection tubes.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 1 week

Methodology

Polymerase Chain Reaction (PCR)/Fluorescence Monitoring/Fragment Analysis

Performed

Varies

Reported

5-10 days

Reference Interval

Interpretive Data

Refer to report.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81232; 81350

Components

Component Test Code* Component Chart Name LOINC
2013096 DPYD Genotype 45284-7
2013097 DPYD Phenotype 79719-1
3017865 DPYD Interpretation 79719-1
3017867 UGT1A1 Genotyping Specimen 66746-9
3017868 UGT1A1 Genotyping Allele 1 51951-2
3017869 UGT1A1 Genotyping Allele 2 51952-0
3017870 UGT1A1 Genotyping Interpretation 34509-0
3017872 EER DPYD UGT1A1 11526-1
3018244 DPYD Genotyping Specimen 31208-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • 5FU drug toxicity
  • Capecitabine
  • Dihydropyrimidine
  • DPD
  • DPYD
  • DPYD genotyping
  • Fegafur
  • Irinotecan Toxicity
  • Uftoral
  • UGT1A1
  • Xeloda
Dihydropyrimidine Dehydrogenase (DPYD) and UPD Glucuronosyltransferase 1A1 (UGT1A1) Genotyping